Abstract
Identifying genetic factors in severe drug eruption should improve efficacy and safety of drug prescription. The first pharmacogenetic studies concerned the polymorphism of genes encoding drug metabolism enzymes (especially for sulfamides reactions in AIDS and anticonvulsants reactions). Recent studies did not confirm the role of genotypic variation in metabolism enzymes in drug reaction. Genes controlling immune response are another research issue. Certain MHC phenotypes are linked to a higher risk of toxidermy, such as in abacavir hypersensitivity or fixed drug eruption. Indeed, severe drug eruptions seem to be linked to a specific immune response controlled by T lymphocytes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
